Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan:168:48-55.
doi: 10.1016/j.ygyno.2022.10.024. Epub 2022 Nov 15.

Molecular testing for endometrial cancer: An SGO clinical practice statement

Christine S Walsh  1 , Kari E Hacker  2 , Angeles Alvarez Secord  3 , Deborah F DeLair  4 , Carolyn McCourt  5 , Renata Urban  6
Affiliations

Molecular testing for endometrial cancer: An SGO clinical practice statement

Christine S Walsh et al. Gynecol Oncol. 2023 Jan.

Abstract

The Cancer Genome Atlas publication first described the genomic landscape of endometrial cancer and characterized these cancers into four molecular subtypes with different prognoses. The Proactive Molecular Classifier for Endometrial Cancer was developed to more easily and inexpensively classify endometrial cancers into four similar molecular subtypes which are termed POLE, mismatch repair deficient, p53 abnormal and no specific molecular profile. Beyond these four subtypes, other molecular biomarkers may influence clinical behavior and response to targeted therapies and include beta-catenin, Her2 amplification, PI3K/mTOR/AKT alterations, L1CAM, hormone receptor expression, tumor mutational burden, and ARID1A. There are numerous clinical trials exploring treatment escalation and de-escalation within the four molecular subtypes as well as matching targeted therapies to specific mutational or biomarker profiles. All endometrial cancers should undergo basic molecular classification that includes assessment of mismatch repair status. POLE and p53 status are prognostic and may become actionable in the future. Clinicians who treat patients with endometrial cancer should understand the role of molecular classification in guiding treatment. The goal of this practice statement is to guide appropriate testing, interpretation, and application of molecular information in endometrial cancer.

Keywords: Biomarkers; Endometrial cancer; Mismatch repair deficiency; Molecular testing; P53; POLE.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Walsh reports grants from Merck, other from Genentech, other from AstraZeneca, other from Immunogen, all outside the submitted work. Dr. Hacker reports other from Strata Oncology, outside the submitted work. Dr. Alvarez Secord reports grants and other from AbbVie, grants from Amgen, grants and other from Astra Zeneca, grants from Boehringer Ingelheim, grants and other from Clovis, grants and other from Eisai, grants from Immutep Ltd., grants and other from Merck, grants and other from Oncoquest, grants from PharmaMar, grants and other from Roche/Genentech, grants from Seagen Inc., grants and other from Tesaro/GSK, grants and other from VBL Therapeutics, grants from National Cancer Trial Network, other from Cordgenics, other from Myriad, other from Aravive, other from Regeneron, all outside the submitted work. Dr. Alvarez Secord serves on the SGO Board of Directors and GOG Foundation Board of Directors and is a CARIS Precision Oncology Alliance Member. Drs. McCourt and Urban report other from UpToDate, outside the submitted work. Dr. DeLair has nothing to disclose.

Substances

LinkOut - more resources